GUTS Earnings

GUTS reported its FY2025Q4 earnings on 2026-03-09, showcasing a revenue of against an estimate of , resulting in a 0% surprise. The EPS was 0, surpassing the expected -0.19 by 0%. The stock experienced a 0% price change on the earnings day and a 0% change over the next five days, reflecting market reactions to the results.

Following GUTS's FY2025Q4 earnings announcement on 2026-03-09, the stock price moved by 0% on the day of the release. Over the subsequent five days, it saw a 0% change. Historically, GUTS's stock price tends to shift by an average of 15.83% in the 10 days leading up to earnings and 10.06% in the 10 days following, providing insight into potential market.

For , analysts estimate GUTS's annual revenue to reach , while the EPS is projected at -0.18. These estimates reflect recent revisions, with revenue estimates unchanged by 0% and EPS estimates revised downward by -72.72% over the past three months, indicating analyst expectation in the company's performance.

The correlation between GUTS's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2025 were unchanged by 0%, while EPS estimates moved revised downward by -72.72%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, GUTS's stock price typically moves by 15.83% in the 10 days before its earnings and 10.06% in the 10 days after. For the upcoming earnings, analysts expect an EPS of -0.18 and revenue of .

The earnings call presents a mixed but overall positive outlook. The company's strategic initiatives, including the Revita therapy and Rejuva program, show promise with significant weight loss results and ongoing clinical trials. Despite increased net loss due to non-cash accounting changes, the cash position is strong, extending into 2027. The Q&A highlighted consistent weight loss data and ongoing efforts for market preparation. However, the lack of specific guidance on RJVA-002 receptor potency could be a concern. Overall, the positive clinical data and strategic planning outweigh the negatives, suggesting a positive stock reaction.